About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
AVEO - AVEO Pharmaceuticals| Previous Close | $5.94 | Open | $5.94 |
| Volume | 151.5K | Market Cap | 149.43M |
| Yield | Last Dividend |
| The Daily Biotech Pulse: Moderna Expands... | 09/16/20 |
| Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Avidity Biosciences Inc (NASDAQ: RNA ) Beigene Ltd (NASDAQ: BGNE ) Bicycle Therapeut... | |
| AVEO Oncology Announces European Urology... | 09/15/20 |
| BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that final overall survival (OS) results from its Phase 3 TIVO-3 study were publ... | |
| AVEO Oncology Regains Full Global Rights... | 09/08/20 |
| BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that it has regained full global rights to ficlatuzumab, AVEO???s potent hepatoc... | |
| Aveo wins dismissal of investor lawsuit ... | 07/24/20 |
| Massachusetts-based drug company Aveo Pharmaceuticals has won dismissal of a proposed class action lawsuit accusing it of misleading investors about t... | |
| AVEO Announces Closing of Public Offerin... | 06/19/20 |
| BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced the closing of its previously announced underwritten public offering of 9,725,00... | |
| AVEO Announces Pricing of $44.6 Million ... | 06/16/20 |
| BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that it has priced its previously announced underwritten public offering of 8,50... | |
| AVEO Announces Proposed Public Offering ... | 06/15/20 |
| BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that it has commenced an underwritten public offering of $40.0 million of shares... | |
| Why Is AVEO (AVEO) Up 24.8% Since Last E... | 05/30/20 |
| AVEO (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | |
| AVEO Announces Change to Virtual Annual ... | 05/27/20 |
| BOSTON--(BUSINESS WIRE)--AVEO Oncology (NASDAQ: AVEO) today announced that due to the public health impact of the novel coronavirus (COVID-19) outbrea... | |
| Why You Shouldn't Bet Against AVEO Pharm... | 05/12/20 |
| AVEO Pharmaceuticals (AVEO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well. | |
| AVEO Oncology Reports First Quarter 2020... | 04/30/20 |
| BOSTON--(BUSINESS WIRE)--AVEO Oncology (NASDAQ: AVEO) today reported financial results for the first quarter ended March 31, 2020 and provided a busin... | |
| AVEO Oncology to Present Final Overall S... | 04/29/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Oncology (NASDAQ: AVEO) today announced that the final overall survival analysis from its pivotal Phase 3 TIVO... | |
| AVEO (AVEO) Up 39.9% Since Last Earnings... | 04/15/20 |
| AVEO (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | |
| AVEO Stops AML Study on Ficlatuzumab Ami... | 03/30/20 |
| AVEO ceases the phase II CyFi-2 study on ficlatuzumab plus high-dose cytarabine for treating patients with relapsed/refractory acute myeloid leukemia ... | |
| Aveo bails on ficlatuzumab study amid Co... | 03/27/20 |
| Citing clinical trial sites' urgent shift towards fighting the COVID-19 pandemic, AVEO Oncology (NASDAQ:AVEO) and collaboration partner Biodesix have ... | |
| AVEO Oncology and Biodesix to Discontinu... | 03/27/20 |
| CAMBRIDGE, Mass. & BOULDER, Colo.--(BUSINESS WIRE)--AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced the discontinuation of their CyFi-... | |
| The Daily Biotech Pulse: Mylan Ramps Up ... | 03/20/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 19.) ... | |
| AVEO Pharmaceuticals (AVEO) Q4 Earnings ... | 03/17/20 |
| Even though AVEO Pharmaceuticals (AVEO) reports narrower-than-estimated loss in the fourth quarter, its revenues miss the mark. | |
| AVEO Pharmaceuticals (AVEO) Reports Q4 L... | 03/16/20 |
| AVEO (AVEO) delivered earnings and revenue surprises of 51.72% and -63.62%, respectively, for the quarter ended December 2019. Do the numbers hold clu... | |
| AVEO Pharmaceuticals beats on revenue | 03/16/20 |
| AVEO Pharmaceuticals (NASDAQ:AVEO): Q4 GAAP EPS of -$0.28. Revenue of $0.76M (-48.6% Y/Y) beats by $0.26M. Cash, cash equivalents and marketable secur... | |
| The Daily Biotech Pulse: Roche Obtains F... | 03/13/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) ... | |
| The Daily Biotech Pulse: Mesoblast To Te... | 03/10/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) A... | |
| AVEO Announces Effectiveness of 1-for-10... | 02/19/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Oncology (NASDAQ: AVEO) today announced that it will effect a 1-for-10 reverse stock split of its common stock... | |
| AVEO Oncology Announces Publication of P... | 02/12/20 |
| AVEO Oncology (NASDAQ: AVEO) today announced the publication of results from a monotherapy trial of tivozanib, the Company???s vascular endothelial gr... | |
| AVEO Posts Data on Ficlatuzumab From Pan... | 01/28/20 |
| AVEO releases results from a phase Ib study on ficlatuzumab in combination with nab-paclitaxel and gemcitabine for treating advanced pancreatic cancer... | |
| AVEO Oncology and Biodesix Announce Resu... | 01/27/20 |
| CAMBRIDGE, Mass. & BOULDER, Colo.--(BUSINESS WIRE)--AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced the presentation of results from a... | |
| AVEO Announces Appointment of Erick J. L... | 01/06/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Erick Lucera as chief financial officer. Mr. Lucera... | |
| Why Is AVEO (AVEO) Down 0.1% Since Last ... | 12/12/19 |
| AVEO (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | |
| Knee Bursitis Treatment Market 2019 Rese... | 11/30/19 |
| Nov 30, 2019 (Market Insight Reports via COMTEX) -- Knee Bursitis Treatment Market report will make detailed analysis mainly on in-depth research on t... | |
| AVEO Oncology to Present at the 31st Ann... | 11/26/19 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will presen... | |
| Strong Buy rating | 08/13/20 |
| SVB Leerink initiates coverage with Outperform rating and announces Price Target of $7.00 | |
| Date | 2020-08-10 (BMO) | Est. (EPS/Rev.) | ($0.51)/ 1.35M |
| Actual (EPS/Rev.) | $-0.42/ $749.00 K | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| LavaPit | Steve Pitkin | 57.00 % | Follow |
| Mojo Day Trading | ProTrader Mike | 46.00 % | Subscribe |
| Long Only Biotech/Pharma | Biotech Buys | 33.00 % | Follow |
| 2kHedgeFund | Cory Cook | 25.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
